+288.2%
CIEN vs GSK
+40.7%
+247.6%
-63.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.8% | -0.1% | -10.6% | -10.8% |
| 7D | -16.5% | -5.3% | -11.1% | -16.1% |
| 30D | -35.1% | -3.7% | -31.5% | -35.0% |
| 3M | -40.3% | -7.3% | -33.0% | -39.8% |
| 6M | -57.8% | -4.2% | -53.5% | -57.8% |
| YTD | +0.2% | +0.9% | -0.7% | -0.7% |
| 1Y | +32.8% | +7.3% | +25.5% | +30.2% |
| 3Y | +421.2% | +52.7% | +368.4% | +362.7% |
| All | +288.2% | +40.7% | +247.6% | +241.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling